1. Home
  2. UBFO vs SGMT Comparison

UBFO vs SGMT Comparison

Compare UBFO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Security Bancshares

UBFO

United Security Bancshares

HOLD

Current Price

$10.63

Market Cap

183.4M

Sector

Finance

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$5.37

Market Cap

204.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UBFO
SGMT
Founded
1987
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
183.4M
204.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
UBFO
SGMT
Price
$10.63
$5.37
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$27.00
AVG Volume (30 Days)
31.9K
527.1K
Earning Date
01-22-2026
03-11-2026
Dividend Yield
4.60%
N/A
EPS Growth
N/A
N/A
EPS
0.70
N/A
Revenue
$48,283,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.32
$1.73
52 Week High
$11.05
$11.41

Technical Indicators

Market Signals
Indicator
UBFO
SGMT
Relative Strength Index (RSI) 60.46 32.94
Support Level $10.35 $5.88
Resistance Level $11.05 $6.15
Average True Range (ATR) 0.26 0.36
MACD 0.02 -0.03
Stochastic Oscillator 62.50 21.98

Price Performance

Historical Comparison
UBFO
SGMT

About UBFO United Security Bancshares

United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: